STOCK TITAN
  1. Home
  2. News
  3. NSTG

Nanostring Technologies Inc - NSTG STOCK NEWS

Welcome to our dedicated news page for Nanostring Technologies (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on Nanostring Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nanostring Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nanostring Technologies's position in the market.

News
NanoString Announces Completion of Financing to Support Restructuring Process
Rhea-AI Summary
NanoString Technologies, Inc. secures $47.5 million in new financing, supporting its mission to serve life sciences researchers worldwide. The funding will aid the company through its restructuring process and support key business activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
91.67%
Tags
none
-
News
NanoString Takes Steps to Restructure Its Business and Protect Its Mission to Map the Universe of Biology
Rhea-AI Summary
NanoString Technologies, Inc. (NSTG) is initiating voluntary Chapter 11 restructuring proceedings to protect its business and explore strategic alternatives, including potential sale of the company. This comes after unfavorable outcomes in patent litigation with competitor 10x Genomics, Inc. The company has secured $40 million in financing to facilitate the process and continue serving life sciences researchers worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-78.72%
Tags
none
-
News
NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability
Rhea-AI Summary
NanoString Technologies, Inc. (NSTG) announced the availability of the CosMx Human 6K Discovery Panel, the first single-cell spatial panel measuring over 6,000 RNA targets. The company will present groundbreaking whole transcriptome imaging capabilities at the AGBT General Meeting. Independent researchers will showcase studies powered by the whole transcriptome panel, highlighting its potential to advance research in areas such as Alzheimer's Disease and colorectal cancer. NanoString will also feature its spatial solutions in ten AGBT-accepted abstracts, demonstrating the innovative technology's potential to revolutionize precision medicine and diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.83%
Tags
none
News
NanoString’s CosMx SMI Achieves Whole Transcriptome Imaging at Single-Cell Resolution
Rhea-AI Summary
NanoString Technologies, a leading life science tools provider (NASDAQ: NSTG), marked a major milestone by releasing the first public dataset of the CosMx Whole Transcriptome Panel, showcasing true single-cell resolution imaging. The company achieved a scientific moonshot by visualizing the expression of almost 19,000 genes in situ, enabling researchers to explore millions of cells per experiment, identify rare cell types, and understand cell-to-cell interactions in spatial context. This transformative technology will be commercially launched in 2025, offering nearly 40x the coverage of competing platforms at a lower cost per single cell and higher cellular throughput. NanoString also plans to launch the CosMx Human 6K Discovery Panel in Q1 2024, empowering researchers to delve deeper into cell states and function, explore intricate cell-to-cell interactions, and deliver new insights into spatial cellular responses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NanoString Reports Inducement Grants Under Nasdaq Listing Rules
Rhea-AI Summary
NanoString Technologies, Inc. (Nasdaq: NSTG) announced equity inducement awards to 10 new employees, granting 34,925 restricted stock units as material inducements. One-third of the RSUs vest on the first market trading day on or following the first anniversary of the grant date and one-third annually each year on the first market trading day on or after the second and third anniversaries of the grant date, subject to continued service. The awards were made outside of NanoString’s current equity plan, the 2022 Equity Incentive Plan, and under NanoString’s 2018 Inducement Equity Incentive Plan and related award agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NanoString to Webcast Presentation from 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
NanoString Technologies, Inc. (NSTG) to present at the 42nd annual J.P. Morgan healthcare conference. Brad Gray, president and CEO, to present on January 10, 2024, at 5:15pm ET. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
conferences
News
NanoString Comments on Delaware District Court Verdict
Rhea-AI Summary
NanoString Technologies, Inc. (NASDAQ: NSTG) commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware, finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages. NanoString plans to seek to have the verdict overturned or amended in post-trial motions and expects to appeal to the U.S. Court of Appeals for the Federal Circuit, specializing in patent disputes. The company remains resolute in its belief that the asserted patents are invalid, that they don’t infringe these patents, and that they should be vindicated on appeal. The verdict does not prevent NanoString from continuing to sell GeoMx products worldwide, and the company is dedicated to enabling scientists to map the universe of biology and saving patients’ lives. NanoString also announced the withdrawal of its full year 2023 and fourth quarter financial guidance, pending a review of the impact of this litigation outcome on its business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-50%
Tags
none
-
News
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies
Rhea-AI Summary
10x Genomics (TXG) Wins Patent Infringement Case Against NanoString, Awarded Over $31 Million in Damages: A jury in the U.S. District Court for the District of Delaware unanimously ruled in favor of 10x Genomics in the patent infringement suit against NanoString, awarding over $31 million in damages for willful infringement of seven patents. The ruling is the third against NanoString in six months, confirming serial infringement of 10x patents. Post-trial, 10x intends to seek ongoing royalties, treble damages, attorney's fees, a permanent injunction, and pre- and post-judgment interest. 10x's Chief Legal Officer emphasized the importance of protecting patents and thanked the jury for recognizing 10x's innovation. The ruling is based on extensive evidence, including testimony from key figures. This case is part of a larger legal battle, with another suit pending against NanoString in the U.S. District Court for the District of Delaware.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience
Rhea-AI Summary
NanoString Technologies (NSTG) to Present Groundbreaking Brain Research at Neuroscience 2023 in Seattle, Including New CosMx™ Mouse Universal Cell Characterization RNA Panel. The company will showcase its digital spatial profiling and spatial imaging platforms, with 22 posters and two symposia at the Society for Neuroscience annual meeting. The presentation will offer insights into single cell signaling for healthy and diseased brain tissue, with potential future patient benefits. The company also secured 22 other poster presentations on various neuro-related topics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
conferences
News
NanoString to Webcast Presentations from Upcoming Healthcare Conferences
Rhea-AI Summary
NanoString Technologies, Inc. (NASDAQ:NSTG) to Present at Stifel 2023 Healthcare Conference and Jefferies London Healthcare Conference. Tom Bailey and Doug Farrell to participate in fireside discussion and corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
conferences
Stock NSTG logo
Nanostring Technologies Inc

Nasdaq:NSTG

NSTG Rankings

N/A Ranked by Market Cap
#5445 Ranked by Stock Gains
N/A Ranked by Dividends

NSTG Stock Data

5.07M
39.41M
3.17%
106.45%
12.55%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Seattle

About NSTG

nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali